Product Information
TREMFYA 100 MG/ML ONE-PRESS is a brand product labeled by Janssen Biotech, Inc., priced at $14743.7181 per ML under NDC 57894064011. Its NADAC has been published 202 times since Nov 23, 2022.
Strength
100 mg/mL
Manufacturer
Janssen Biotech, Inc.NDC
57894064011
Classification
Brand
Dosage Form
INJECTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
GUSELKUMABApproval Type
Biologic (BLA)
FDA Application
BLA761061On Market Since
7/13/2017
Pharmacological Classes
Price Statistics
The NADAC for TREMFYA 100 MG/ML ONE-PRESS has been published 202 times since Nov 23, 2022, and over the history we have for it it has risen 20.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $14743.7181 per ML |
|---|---|
| All-time high | $14766.3280 (Jun 10, 2026) |
| All-time low | $12239.5220 (Nov 23, 2022) |
| 52-week high | $14766.3280 |
| 52-week low | $14031.2512 |
| Median price | $13494.0730 |
| Average price | $13599.5758 |
| Largest weekly change | +5.0% (Jan 31, 2024) |
| Weeks tracked | 202 |
| Tracking since | Nov 23, 2022 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Janssen Biotech, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Guselkumab market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Interleukin-23 Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TREMFYA 100 MG/ML ONE-PRESS?
The current National Average Drug Acquisition Cost (NADAC) for TREMFYA 100 MG/ML ONE-PRESS, manufactured by Janssen Biotech, Inc., is $14743.7181 per ML (NDC 57894064011), effective Sep 30, 2026.
How has the price of TREMFYA 100 MG/ML ONE-PRESS changed over time?
Over the history we have for it, the NADAC for TREMFYA 100 MG/ML ONE-PRESS has risen 20.5%. It has been tracked across 202 weekly CMS publications since Nov 23, 2022.
What are the highest and lowest recorded NADAC prices for TREMFYA 100 MG/ML ONE-PRESS?
Since Nov 23, 2022, the NADAC for TREMFYA 100 MG/ML ONE-PRESS has ranged from a low of $12239.5220 (Nov 23, 2022) to a high of $14766.3280 (Jun 10, 2026), with a median of $13494.0730 per ML.
Are there cheaper alternatives to TREMFYA 100 MG/ML ONE-PRESS?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TREMFYA 100 MG/ML SYRINGE, is $14728.9053 per ML — about 0% below TREMFYA 100 MG/ML ONE-PRESS.
Who manufactures TREMFYA 100 MG/ML ONE-PRESS?
TREMFYA 100 MG/ML ONE-PRESS (NDC 57894064011) is labeled by Janssen Biotech, Inc., and CMS classifies it as a brand product.